ATHE
BEARISH
$3.55
Live
Alterity Therapeutics Limited · NASDAQ
Target $12.0
(+238.0%)
$2.52
52W Range
$7.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$64.35M
P/E
N/A
ROE
-43.2%
Profit margin
-223.3%
Debt/Equity
0.0
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score limits bankruptcy risk assessment. Despite strong revenue growth of 80.90% YoY and a pristine balance sheet with zero debt and a current ratio of 12.98, the company is deeply unprofitable with a profit margin of -223.35% and negative ROE of -43.23%. Valuation metrics are extreme, with a Price/Book of 1038.03 and a negative Forward P/E of -4.49, suggesting significant overvaluation relative to book and earnings. While insider sentiment is moderately positive at 40/100 and analysts project a high target price of $12.00, the lack of profitability, inconsistent cash flow data, and weak technical trend (0/100) raise serious concerns about sustainability.
Key Strengths
Exceptional revenue growth of 80.90% YoY, significantly above sector average of 23.74%
Zero debt with a Debt/Equity ratio of 0.00, indicating strong capital structure flexibility
Very high liquidity with Current Ratio of 12.98 and Quick Ratio of 12.62
Perfect quarterly earnings surprise record: 2/2 beats with 100% average surprise
Gross margin of 97.66% reflects high-margin biotech business model
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and limited profitability strength
Extremely high valuation: Price/Book of 1038.03 and negative Forward P/E suggest severe overvaluation
Deeply negative profitability: Profit margin of -223.35% and ROE of -43.23% signal ongoing losses
No Altman Z-Score available, creating uncertainty around bankruptcy risk
Lack of cash flow data (Free Cash Flow, Operating Cash Flow = N/A) obscures true financial viability
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
20
65
50
45
0
AI Verdict
High-risk speculative biotech with unsustainable valuation and weak profitability despite strong growth and clean balance sheet
Key drivers: Revenue growth (positive), Profitability metrics (negative), Valuation multiples (negative), Piotroski F-Score (negative), Liquidity position (positive)
Confidence
70%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Graham Number not applicable due to unprofitability
Watchpoints
- Price/Book of 1038.03 is extremely elevated
- Forward P/E of -4.49 indicates negative earnings
- No meaningful intrinsic value calculation possible due to losses
Future
65/100
Ref Growth rates
Positives
- Revenue growth of 80.90% YoY is robust
- Analyst target price of $12.00 implies 239% upside
Watchpoints
- Earnings growth data unavailable
- No visibility on path to profitability
Past
50/100
Ref Historical trends
Positives
- Perfect earnings surprise history (2/2 beats)
- 1Y price return of +6.3% outperforms sector median
Watchpoints
- 5Y price change of -80.8% indicates long-term underperformance
- 6M return of -45.8% shows recent volatility and weakness
Health
45/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.00 eliminates leverage risk
- Current and Quick Ratios above 12 indicate exceptional short-term liquidity
Watchpoints
- Piotroski F-Score of 4/9 reflects weak financial health
- No Altman Z-Score available for distress risk assessment
- ROE of -43.23% and ROA of -28.09% indicate poor asset utilization
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.55
Analyst Target
$12.0
Upside/Downside
+238.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATHE and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics Limited
Primary
|
-80.8% | -8.5% | +6.3% | -45.8% | +14.5% | +2.9% |
|
XGN
Exagen Inc.
Peer
|
-83.8% | +7.2% | -53.1% | -77.5% | -2.2% | -12.1% |
|
ICCC
ImmuCell Corporation
Peer
|
-21.2% | +44.8% | +39.6% | +4.1% | +6.5% | +9.9% |
|
NSPR
InspireMD, Inc.
Peer
|
-78.0% | +31.1% | -45.1% | -43.3% | -17.7% | -1.5% |
|
FORA
Forian Inc.
Peer
|
-82.8% | -35.5% | +13.5% | -7.0% | +2.9% | +1.9% |
ATH
Alterity Therapeutics Limited
Primary
5Y
-80.8%
3Y
-8.5%
1Y
+6.3%
6M
-45.8%
1M
+14.5%
1W
+2.9%
XGN
Exagen Inc.
Peer
5Y
-83.8%
3Y
+7.2%
1Y
-53.1%
6M
-77.5%
1M
-2.2%
1W
-12.1%
ICC
ImmuCell Corporation
Peer
5Y
-21.2%
3Y
+44.8%
1Y
+39.6%
6M
+4.1%
1M
+6.5%
1W
+9.9%
NSP
InspireMD, Inc.
Peer
5Y
-78.0%
3Y
+31.1%
1Y
-45.1%
6M
-43.3%
1M
-17.7%
1W
-1.5%
FOR
Forian Inc.
Peer
5Y
-82.8%
3Y
-35.5%
1Y
+13.5%
6M
-7.0%
1M
+2.9%
1W
+1.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.49
PEG Ratio
N/A
P/B Ratio
1038.03
P/S Ratio
11.83
EV/Revenue
6003.13
EV/EBITDA
-2231.26
Market Cap
$64.35M
Profitability
Profit margins and return metrics
Profit Margin
-223.35%
Operating Margin
-185.73%
Gross Margin
97.66%
ROE
-43.23%
ROA
-28.09%
Growth
Revenue and earnings growth rates
Revenue Growth
+80.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.0
Low debt
Current Ratio
12.98
Strong
Quick Ratio
12.62
Excellent
Cash/Share
$0.0
Quarterly Earnings History
EPS performance vs analyst estimates
2015-08-25
$N/A
+100.0% surprise
2013-02-26
$N/A
+100.0% surprise
Healthcare Sector Comparison
Comparing ATHE against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-43.23%
This Stock
vs
-88.14%
Sector Avg
-51.0%
(Below Avg)
Profit Margin
-223.35%
This Stock
vs
-16.28%
Sector Avg
+1271.9%
(Superior)
Debt to Equity
0.0
This Stock
vs
2.66
Sector Avg
-99.9%
(Less Debt)
Revenue Growth
80.9%
This Stock
vs
124.04%
Sector Avg
-34.8%
(Slower)
Current Ratio
12.98
This Stock
vs
4.47
Sector Avg
+190.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics Limited
|
BEARISH | $64.35M | - | -43.2% | -223.3% | $3.55 | |
|
XGN
Exagen Inc.
|
BEARISH | $64.46M | - | -147.8% | -30.0% | $2.68 | Compare |
|
ICCC
ImmuCell Corporation
|
BEARISH | $64.01M | - | -3.8% | -3.8% | $7.08 | Compare |
|
NSPR
InspireMD, Inc.
|
BEARISH | $63.18M | - | -106.9% | -% | $1.35 | Compare |
|
FORA
Forian Inc.
|
BEARISH | $66.86M | - | -9.6% | -9.5% | $2.14 | Compare |
ATHE
Alterity...
BEARISH
Mkt Cap
$64M
P/E
-
ROE
-43.2%
Price
$3.55
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
Canaccord Genuity
2025-12-17
Speculative Buy
Past News Coverage
Recent headlines mentioning ATHE from our newsroom.
Newest → oldest
No matching news yet.